Curis Inc
CRIS1.430USD
-0.030-2.05%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
15.31MCap. mercado
PérdidaP/E TTM
Más Datos de Curis Inc Compañía
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Información de Curis Inc
Símbolo de cotizaciónCRIS
Nombre de la empresaCuris Inc
Fecha de salida a bolsaAug 01, 2000
Director ejecutivoMr. James E. Dentzer
Número de empleados33
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 01
Dirección128 Spring Street
CiudadLEXINGTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02421
Teléfono16175036500
Sitio Webhttps://www.curis.com/
Símbolo de cotizaciónCRIS
Fecha de salida a bolsaAug 01, 2000
Director ejecutivoMr. James E. Dentzer
Ejecutivos de Curis Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. James E. Dentzer
Mr. James E. Dentzer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
8.39K
+37.97%
Ms. Diantha Duvall
Ms. Diantha Duvall
Chief Financial Officer
Chief Financial Officer
4.90K
+660.71%
Dr. Kenneth I. Kaitin, Ph.D.
Dr. Kenneth I. Kaitin, Ph.D.
Independent Director
Independent Director
1.41K
--
Mr. Martyn D. Greenacre
Mr. Martyn D. Greenacre
Independent Chairman of the Board
Independent Chairman of the Board
1.30K
--
Dr. Jonathan Zung, Ph.D.
Dr. Jonathan Zung, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
Dr. Marc Rubin, M.D.
Dr. Marc Rubin, M.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. James E. Dentzer
Mr. James E. Dentzer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
8.39K
+37.97%
Ms. Diantha Duvall
Ms. Diantha Duvall
Chief Financial Officer
Chief Financial Officer
4.90K
+660.71%
Dr. Kenneth I. Kaitin, Ph.D.
Dr. Kenneth I. Kaitin, Ph.D.
Independent Director
Independent Director
1.41K
--
Mr. Martyn D. Greenacre
Mr. Martyn D. Greenacre
Independent Chairman of the Board
Independent Chairman of the Board
1.30K
--
Dr. Jonathan Zung, Ph.D.
Dr. Jonathan Zung, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Bleichroeder LP
8.29%
Armistice Capital LLC
7.20%
Satterfield (Thomas A Jr)
7.09%
Maverick Capital, Ltd.
5.45%
M28 Capital Management LP
4.17%
Otro
67.80%
Accionistas
Accionistas
Proporción
Bleichroeder LP
8.29%
Armistice Capital LLC
7.20%
Satterfield (Thomas A Jr)
7.09%
Maverick Capital, Ltd.
5.45%
M28 Capital Management LP
4.17%
Otro
67.80%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
17.99%
Hedge Fund
13.93%
Individual Investor
7.23%
Investment Advisor/Hedge Fund
1.78%
Research Firm
0.77%
Otro
58.29%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
81
4.31M
34.48%
-767.17K
2025Q2
101
5.57M
44.60%
+1.30M
2025Q1
112
5.58M
53.29%
+1.28M
2024Q4
119
3.88M
45.77%
+849.35K
2024Q3
129
2.03M
33.69%
-831.36K
2024Q2
151
2.33M
39.45%
-531.00K
2024Q1
226
2.12M
35.82%
-1.17M
2023Q4
249
2.07M
35.17%
-1.64M
2023Q3
265
2.42M
42.19%
-1.36M
2023Q2
279
1.78M
36.08%
-2.05M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Bleichroeder LP
1.04M
8.29%
--
--
Jun 30, 2025
Armistice Capital LLC
899.92K
7.2%
-133.44K
-12.91%
Jun 30, 2025
Satterfield (Thomas A Jr)
886.71K
7.09%
+274.49K
+44.84%
Mar 31, 2025
Maverick Capital, Ltd.
681.38K
5.45%
+49.55K
+7.84%
Jun 30, 2025
M28 Capital Management LP
521.06K
4.17%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
303.19K
2.43%
--
--
Jun 30, 2025
CM Management, LLC
220.00K
1.76%
-20.00K
-8.33%
Jun 30, 2025
Renaissance Technologies LLC
100.47K
0.8%
+3.60K
+3.72%
Jun 30, 2025
Citi Investment Research (US)
91.87K
0.73%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
85.31K
0.68%
-1.03K
-1.19%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
Fecha
Tipo
Relación
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
